Planning Committee:

Dr. Wendy Lam, BSc. (Pharm), FRCPC,
Director BC Community Oncology Trialists,
Burnaby Hospital Regional Cancer Centre,
Burnaby, BC

Dr. Wendy Lam is a hematologist and medical oncologist at the Burnaby Hospital Regional Cancer Centre.  She received her B.Sc (Pharmacy) at Dalhousie University and her MD from University of British Columbia. She then completed her Internal Medicine residency at UBC and Hematology fellowship at McMaster University.

She is the Founding Director of the British Columbia Community Oncology Trialists (BC COT), which is a collaborative group of oncologists and hematologists involved in clinical research.

Her other interests include education of patients through meeting with patient groups. She has also been instrumental in organizing meetings for continued medical education.

She is Director of the Society of Hematology and Oncology of BC at British Columbia Medical Association.

Dr. Mitchell C.C. Liu, MDCM, FRCPC
Clinical Associate Professor
University of British Columbia (UBC)
Radiation Oncologist, British Columbia Cancer Agency (BCCA)
Director of Lung Cancer Radiation Oncology (BCCA)
Vancouver, BC

Dr. Liu is a Clinical Associate Professor of Radiation Oncology in the Department of Surgery, University of British Columbia.  Dr. Liu completed his radiation oncology residency at McGill University and a radiation oncology fellowship at Massachusetts General Hospital in Boston.

He practices at the BC Cancer, Vancouver Centre and currently in the Lung ( Disease Site Director )and GI team.  Dr. Liu’s particular areas of interest include: SBRT (Lung, Liver, Spine, and Oligometastases); risk factors and predictive models for radiation therapy complications.

Dr. Barbara Melosky, MD, FRCPC
Clinical Professor of Medicine, University of British Columbia
Medical Oncologist, British Columbia Cancer Agency
Vancouver, BC

Dr. Melosky is a Clinical Professor of Medicine at the University of British Columbia and a Medical Oncologist at the British Columbia Cancer Agency.

She graduated from medical school at the University of Manitoba and did a residency in internal medicine at the University of British Columbia.

She is currently a medical oncologist at the BC Cancer Agency with clinical interests in GI and respiratory malignancies.

She is also the chairperson of the Colorectal Screening Program of British Columbia and has a special interest in EGFR receptors and management of side effects.


Dr. Deepu Alex, MD
Department of Pathology and Laboratory Medicine
BC Cancer
Vancouver, BC

Deepu Alex, M.D., Ph.D., is a Pathologist at BC Cancer Agency in Vancouver. He is certified by the American Board of Pathology in Anatomic Pathology, Clinical Pathology, Molecular Genetic Pathology and Cytopathology. He received his medical degree from St. John’s Medical College in Bangalore, India and his doctoral degree in Microbiology and Immunology from Georgetown University, Washington D.C. He completed his residency training in Anatomic and Clinical Pathology at Medstar-Georgetown University Hospital, Washington D.C. He has completed fellowship training in Oncologic Surgical Pathology, Molecular Genetic Pathology and Cytopathology at Memorial Sloan-Kettering Cancer Center, New York. He is actively involved in various professional societies in Pathology. His areas of research interest include molecular testing of cytology specimens, molecular profiling of lung cancers and, development of advanced molecular techniques for clinical testing.

Dr. Puneet Bains, MD
Vancouver, BC

Puneet Bains hails from Vancouver, BC. She is a Medical Oncologist at Lions Gate hospital in North Vancouver.  She did her Internal Medicine training in Syracuse, NY. As an avid sports fan, she was on the pursuit of a sports medicine career and went to Syracuse, well known for college sports, but soon changed her path to Oncology.  She returned to the University of British Columbia to complete her Medical Oncology training.

She is one of the directors of the British Columbia Community Oncology Trialists (BC COT), which is a collaborative group of oncologists and hematologists involved in clinical research.  Clinical interests include breast cancer and current clinical research in breast, lung, melanoma clinical trials.

Dr. Normand Blais, MD
Associate Professor at University of Montreal
Montreal, Quebec

Dr. Normand Blais obtained his MD at Sherbrooke University and obtained hematology and medical oncology certificates from Montreal University. After 10 years in practice, Normand went into sabbatical to obtain his Masters in Translational Science at McMaster University. Dr. Blais is an associate professor at University of Montreal and chair of the thoracic oncology clinical and research program of the CHUM cancer center. He is also the founder of the groupe d’étude en oncologie du Québec web site ( and founder of the Quebec lung cancer research network.

Dr. Elisa Chan, MD
Department of Radiation Oncology
BC Cancer, Vancouver BC

Dr. Elisa Chan is a radiation oncologist at the BC Cancer, Vancouver Centre.  Her clinical focus is on lung and breast cancers.   She completed her medical school and radiation oncology residency training at the University of Toronto.  Part of her fellowship training at the BC Cancer, Vancouver Centre involved trying to improve screening mammography rates in overdue women in BC.

Dr. Kim Chi
Associate Director, Clinical Research, Vancouver Prostate Centre
Senior Research Scientist, Vancouver Prostate Centre
Regional Medical Director, BC Cancer Agency – Vancouver Centre
Medical Oncologist, BC Cancer Agency – Vancouver Centre
Director, Clinical Research, BC Cancer Agency
Professor, Department of Medicine, UBC

Dr. Chi is a medical oncologist with the BC Cancer Agency who, at a relatively early stage in his career, has received national and international recognition for his contributions to prostate cancer research.

Dr. Chi’s research is focused in the area of genitourinary cancers with a special interest in prostate cancer and investigational new drugs.  This includes phase I, II and III clinical trials, therapeutic use of antisense oligonucleotides and mechanisms of treatment resistance. He has had peer reviewed grant funding for the conduct of early phase clinical trials and associated correlative studies from the Canada Institutes of Health Research (CIHR), Canadian Cancer Society Research Institute, The U.S. Department of Defense, the Prostate Cancer Foundation (USA), Movember and Prostate Cancer Canada.  Nationally and internationally he has led a number of multi-centre Phase I, II and III clinical trials including cooperative group studies and investigator sponsored studies with agents sourced from the US National Cancer Institute’s Cancer Therapy Evaluation Program (NCI CTEP) and industry collaborators. He has led the phase I through III development of two novel compounds (OGX-011 and OGX-427), which came from academic preclinical development at the Vancouver Prostate Centre. He has also contributed to clinical trials that established new standard of care for patients with advanced prostate cancer (docetaxel, abiraterone acetate, enzalutamide).

Dr. Chi is currently the medical director of the Clinical Trials Unit at the BC Cancer Agency – Vancouver Centre and Professor with the Department of Medicine at the University of British Columbia. He was appointed Chair of the Genitourinary Systemic Group at the BC Cancer Agency in 2003. This group is responsible for developing systemic treatment management guidelines for patients with genitourinary cancers in the province of British Columbia (available at and securing access to new therapies through the province’s health care system.  Under his guidance as medical director of the Clinical Trials Unit at the BC Cancer Agency – Vancouver Centre (which provides access for patients to the latest in investigational new drugs through phase I, II and III clinical studies), the not-for-profit Clinical Trials Unit almost doubled patient accrual to trials, becoming a self-sustaining growth operation.

Dr. Chi is also the Co-Chair of the Genitourinary Disease Site for the Canadian Cancer Trials Group (CCTG) and the Canadian Uro-Oncology Group, which is responsible for developing the genitourinary cancer trials undertaken by investigators at a national cooperative group level. In addition, he is an Executive Committee Member and Past-Chair of the Investigational New Drug Site for the CCTG, which is responsible for developing early phase I/II trials across the CCTG disease sites.

Richard S. Finn, MD
Professor of Clinical Medicine
Division of Hematology/ Oncology
UCLA David Geffen School of Medicine
University of California, Los Angeles

Dr Finn is a Professor of Clinical Medicine in the Division of Hematology/ Oncology at the UCLA David Geffen School of Medicine and Director of the Signal Transduction Program in the Jonsson Comprehensive Cancer Center at UCLA.

He currently splits his time between patient care and laboratory and clinical research.  His research interests lie in the development of molecular targeted agents and biomarkers in liver cancer and breast cancer.  Dr Finn has served as principal and sub-investigator in trials exploring the use of targeted therapies in breast and hepatocellular cancers. He has a particular interest in identifying predictive markers of response to novel therapeutics. His work has been published in journals such as the New England Journal of Medicine, The Lancet, Journal of Clinical Oncology, Lancet Oncology, Cancer Research, Clinical Cancer Research, Hepatology, Cancer Cell and elsewhere. Dr Finn has also given oral presentations at major meetings including American Society of Clinical Oncology (ASCO), European Cancer Conference (ECCO/ ESMO), and the American Association of Cancer Research (AACR) and others.  Most recently, he has led the approval of palbociclib (Ibrance), the first CDK 4/6 inhibitor in cancer medicine, from pre-clinical development to global registration.

Dr Finn is a member of ASCO, American Association of Cancer Research (AACR) and the European Society of Medical Oncology.  He is a senior editor of Clinical Cancer Research and Breast Cancer Research.

Dr. Sharlene Gill, BSC (PHARM), MD, MPH, FACP, FRCPC
Professor of Medicine at the University of British Columbia
Staff Oncologist at the BC Cancer Agency
Vancouver, BC

Dr. Sharlene Gill is a medical oncologist specializing in gastrointestinal (GI) malignancies. She received a Bachelor’s of Science in Pharmacy (Honors) and an MD (Doctor of Medicine) from the University of British Columbia in 1996 followed by residencies in Internal Medicine and Medical Oncology. Dr. Gill subsequently completed a fellowship in Gl Oncology at the Mayo Clinic (Rochester, MN) and a Master’s of Public Health from the Harvard School of Public Health (Boston, MA) before returning to Vancouver, Canada where she is presently a Professor of Medicine at the University of British Columbia and staff oncologist at the BC Cancer Agency.

Dr. Gill’s areas of expertise are colorectal, pancreatic and hepatobiliary cancers. In addition to her clinical work, she is actively engaged in education and research, with over 80 peer-reviewed publications and book chapters to her credit. She is currently an MBA Candidate at Kenan-Flagler Business School (University of North Carolina, Class of 2017).

Areas of specialization: GI cancers, development of novel therapies, medical education

Dr. Richard J. Gralla,
Director of Oncology Research, Jacobi Medical Center,
Albert Einstein College of Medicine,
Professor of Medicine, New York, NY

Richard J. Gralla is currently the director of oncology research, Jacobi Medical Center, Albert Einstein College of Medicine, and professor of medicine, in New York.

His previous positions include chief of the Thoracic Oncology Service at Memorial Sloan-Kettering Cancer Center (New York), and later director of the Ochsner Cancer Institute in New Orleans, Louisiana. He was then associate director, Herbert Irving Comprehensive Cancer Center, and professor of medicine, at Columbia University, in New York, and then vice president for cancer services, chief of the Division of Hematology and Oncology at the Monter Cancer Center of the Northwell Health System in Lake Success, New York, and professor of medicine, at Hofstra University, Hempstead, New York.

Dr. Gralla received his medical degree from the University of Virginia in Charlottesville.  He completed a fellowship in medical oncology and was a National Cancer Institute fellow in clinical research at Memorial Sloan-Kettering Cancer Center.

Dr. Gralla is the author or co-author of nearly 300 scientific articles and book chapters. His work has been published in journals such as the New England Journal of Medicine, Annals of Internal Medicine, Journal of Clinical Oncology, Cancer, and Cancer Research. He has served on the editorial boards of Cancer, Lung Cancer, and Supportive Care in Cancer.  He holds memberships in the American Society of Clinical Oncology, the American Association for Cancer Research, the International Association for the Study of Lung Cancer, and the Oncology Nursing Society.  Dr. Gralla is the past-president of the Multinational Association of Supportive Care in Cancer and past-president of the New York Lung Cancer Alliance.


Dr. Kyle Grant

Dr. Kyle Grant is a Thoracic Surgeon at Vancouver General Hospital.  He completed his medical school training and General Surgery residency at the University of Manitoba.  He subsequently completed his Thoracic Surgery Fellowship at the University of British Columbia and also holds a Masters Degree from the School of Population and Public Health at UBC.  His interests are Thoracic Oncology and Minimally Invasive Thoracic Surgery.

Dr. Christian Kollmannsberger, MD, FRCPC

Christian Kollmannsberger, MD, FRCPC, is staff medical oncologist at the British Columbia Cancer Agency (BCCA) Vancouver Cancer Centre and Clinical Professor at the University of British Columbia. He graduated from the Technical University in Munich, Germany and received his clinical training in internal medicine, haematology and medical oncology, mainly at University of Tuebingen, Germany. Dr. Kollmannsberger’s research is focused on genito-urinary malignancies with a special interest in testicular and renal cell cancer. This includes phase I, II and III clinical trials, the development of new therapeutic options and investigation of mechanisms of treatment resistance. Nationally and internationally, he has contributed to numerous trials in the field of renal cell carcinoma and testicular cancer. Currently, Dr. Kollmannsberger serves as chair of the BC Cancer Agency Genitourinary Cancers Systemic Therapy Group, chair for the Genitourinary Clinical Trials Unit at BC Cancer Vancouver Centre, chair for the National Cancer Institute of Canada Testis Cancer Disease Oriented Group, and member of the National Cancer Institute of Canada Kidney Cancer Disease Oriented Group.

Dr. John L. Marshall, MD
Chief, Hematology and Oncology
Professor of Medicine and Oncology
Director, Otto J Ruesch Center for the Cure of Gastrointestinal Cancers
Lombardi Comprehensive Cancer Center
Georgetown University
Washington DC

Dr. Marshall received his training at Duke University, the University of Louisville, and Georgetown University. Dr. Marshall is an internationally recognized expert in new drug development for GI cancer, with expertise in phase I, II, and III trial design, and has served as Principal Investigator for more than one hundred clinical trials.  While he has an interest in many areas of cancer research, his primary focus has been on the development of vaccines to treat cancer. Dr. Marshall has become an outspoken advocate for GI cancer patients and the importance of clinical research participation. In 2009, he established the Otto J Ruesch Center for the Cure of GI Cancers, an organization solely focused on improving the lives of GI cancer patients through innovative research, personalized medicine, and focused advocacy. In 2015, Dr. Marshall both established and directs the Precision Oncology Alliance, a national alliance established to study the impact of molecular profiling on cancer research, value and outcomes.

Dr. Kevin Song, MD, FRCPC
Clinical Associate Professor
Vancouver General Hospital

Dr. Kevin Song trained in Hematology and then as a Leukemia/Bone Marrow Transplant Fellow in Vancouver from 1998-2000. He did further bone marrow transplant training in Toronto before joining the Leukemia/Bone Marrow Transplant Program Attending Staff in August 2002. His current interests include the treatment of myeloma and other plasma cell dyscrasias and the use of hematopoietic stem cell transplant to treat non-Hodgkin’s lymphoma.

Dr. Simon Yu

Dr. Simon Yu is a medical oncologist practising at Burnaby Hospital and Ridge Meadows Hospital Cancer Clinic.

Dr. John Yun

Community Oncology Practice in Richmond, BC since 1995.  Interested in diagnosis, treatment and palliative care of patients with common malignancies including Breast Cancer, Lung Cancer, and GI Primary. Appointed as UBC Clinical Associate Professor and Active Board Member for BC Community Oncologist.  Father of 7 and never bored.